PMID- 24596453
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140408
LR  - 20211021
IS  - 1177-5475 (Print)
IS  - 1177-5491 (Electronic)
IS  - 1177-5475 (Linking)
VI  - 8
DP  - 2014
TI  - Therapeutic vaccines and cancer: focus on DPX-0907.
PG  - 27-38
LID - 10.2147/BTT.S55196 [doi]
AB  - In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, 
      we developed a novel non-emulsion depot-forming vaccine platform called DepoVax 
      (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented 
      by cancer cells were used as antigens to create a therapeutic cancer vaccine, 
      DPX-0907. In a phase I clinical study, the safety and immune-activating potential 
      of DPX-0907 in advanced-stage breast, ovarian, and prostate cancer patients were 
      examined, following encouraging results in HLA-A2 transgenic mice. The DPX-0907 
      vaccine was shown to be safe and well tolerated, with injection-site reactions 
      being the most commonly reported adverse event. Vaccinated cancer patients 
      exhibited a 61% immune response rate, with higher response rates in the breast 
      and ovarian cancer patient cohorts. In keeping with the higher immune efficacy of 
      this vaccine platform, antigen-specific responses were detected in 73% of immune 
      responders after just one vaccination. In 83% of responders, peptide-specific 
      T-cells were detected at two or more time points post-vaccination, with 64% of 
      these patients showing evidence of immune persistence. Immune monitoring also 
      demonstrated the generation of antigen-specific T-cell memory, with the ability 
      to secrete multiple type 1 cytokines. The novel DPX formulation promotes 
      multifunctional effector/memory responses to peptide-based tumor-associated 
      antigens. The data support the capacity of DPX-0907 to elicit type-1 biased 
      immune responses, warranting further clinical development of the vaccine. In this 
      review, we discuss the rationale for developing DPX-based therapeutic cancer 
      vaccine(s), with a focus on DPX-0907, aimed at inducing efficient anti-tumor 
      immunity that may eventually be shown to prolong patient survival.
FAU - Karkada, Mohan
AU  - Karkada M
AD  - ImmunoVaccine Inc, Dalhousie University, Halifax, NS, Canada ; Department of 
      Microbiology/Immunology, Dalhousie University, Halifax, NS, Canada.
FAU - Berinstein, Neil L
AU  - Berinstein NL
AD  - Ontario Institute for Cancer Research, Toronto, ON, Canada.
FAU - Mansour, Marc
AU  - Mansour M
AD  - ImmunoVaccine Inc, Dalhousie University, Halifax, NS, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140210
PL  - New Zealand
TA  - Biologics
JT  - Biologics : targets & therapy
JID - 101321511
PMC - PMC3930480
OTO - NOTNLM
OT  - DPX-0907
OT  - DepoVax
OT  - cancer vaccine
OT  - immunotherapy
EDAT- 2014/03/07 06:00
MHDA- 2014/03/07 06:01
PMCR- 2014/02/10
CRDT- 2014/03/06 06:00
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/03/07 06:01 [medline]
PHST- 2014/02/10 00:00 [pmc-release]
AID - btt-8-027 [pii]
AID - 10.2147/BTT.S55196 [doi]
PST - epublish
SO  - Biologics. 2014 Feb 10;8:27-38. doi: 10.2147/BTT.S55196. eCollection 2014.